Anti-ASGR-1 monoclonal inhibitory antibodies
US12331122B2 · kind B2 · utility
0Cited by
79References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2020 |
| Grant date | Jun 17, 2025 |
| Priority date | — |
| Expiry date | Jul 13, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.